Q: I’m trying to improve my nutrition, but it’s not easy. Can you help me feel more motivated, please? — Jenny T., Evanston, Ill.

Q: I used to be a serious exerciser, but now that I am in my late 60s, I find it harder and harder to stay on track. Got any ...

In this population-based cohort study, patients with type 2 diabetes who received glucagon-like peptide-1 receptor agonists had a higher risk of developing gastroesophageal reflux disease and ...

The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

101 reported reactions of this kind linked to exenatide, three people died. 52 reported reactions of this sort linked to dulaglutide and 11 reported reactions lixisenatide. No fatalities were linked ...

Why digital measurements startup Koneksa Health thinks it can help pharma measure if their drugs are effective in people with Parkinson's disease.

In a phase 2, double-blind, randomized, placebo-controlled trial, researchers assessed the effect of lixisenatide on the progression of motor disability in patients with Parkinson disease.

In a multicenter clinical trial, patients with early-stage Parkinson’s disease treated with lixisenatide, a drug currently used for the treatment of diabetes, showed improvement in their motor ...

Conclusions In sum, this phase 2 trial showed that lixisenatide, administered in an on-medication state, had a three-point improvement on a motor disability scale over 12 months compared to baseline.

An Ozempic-like drug used to treat diabetes, called lixisenatide, helped slow the progression of motor disability in patients in an early stage of Parkinson's disease, according to the results of ...